TY - JOUR T1 - Simulating drug effects on blood glucose laboratory test time series with a conditional WGAN JF - medRxiv DO - 10.1101/2020.07.19.20157321 SP - 2020.07.19.20157321 AU - Alexandre Yahi AU - Nicholas P. Tatonetti Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/21/2020.07.19.20157321.abstract N2 - The unexpected effects of medications has led to more than 14 million drug adverse events reported to the Food and Drug Administration (FDA) over the past 10 years in the United States alone, with a little over 1.3 million of them linked to death, and represents a medical and financial burden on our healthcare. Laboratory tests have the potential to capture inter-individual variability in drug responses, but a significant portion of the patient population has unique treatment pathways that impedes forecasting and optimal decision making.Generative Adversarial Networks (GANs) are flexible implicit generative models that have demonstrated their ability to capture complex correlations in field like computer vision and natural language. Their latent representation capacity is an opportunity for drug effect simulation on laboratory test trajectories. In this paper, we developed and evaluated conditional GANs on glucose laboratory tests in patients exposed to drug combinations and showed a proof of concept for these models in the simulation of unseen drug combinations. By using conditional Wasserstein GANs (WGANs) to simulate drug effects in laboratory tests, we hope to pave the way for novel clinical decision support (CDM) systems and enable the development of better predictive models for rare cohorts of patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by NIH grants 5R01GM107145 and 1R35GM131905 to AY and NPT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is approved by the Columbia University Irving Medical Center Institutional Review Board (IRB# AAAL0601) and the requirement for an informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study was conducted with electronic health records (EHR) data from Columbia University Irving Medical Center (CUIMC) and is not publicly available for HIPAA compliance. ER -